

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	
		Filing Date	
		First Named Inventor	Ashley Davis
		Group Art Unit	
		Examiner Name	
Sheet	1 of 1	Attorney Docket Number	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials ¹	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
DL	1.	A. Davis et al. Novel suicide ligands of tubulin arrest cancer cells in S-phase. Neoplasia, 1 (6), p.498-507. 1999.	
DL	1.2	Jaing J.D. et al. Synthesis, cancericidal and anti-microtubule activities of 3-haloacetamido-benzoyl-ureas. Anti-Cancer Drug Design, 13 (7), p.735-747. 1998.	
X	12	Jiang J.D. et al. 1998. Inhibition of microtubule assembly in tumor cells by 3-bromoacetyl amino benzoylurea, a new cancericidal compound. Cancer Research, 58, p.2126-2133.	
X	13	Jiang J.D. et al. 1998. 3-iodoacetamido-benzoylurea A novel cancericidal tubulin ligand that inhibits microtubule polymerization, phosphorylates bcl-2 and induces apoptosis in tumor cells. Cancer Research, 58, 5389-5395.	
X	33	Shan B. et al. 1999. Selective covalent modification of beta-tubulin residue Cys-239 by T138067, an antitumor agent with in vivo efficacy against multi-drug resistant tumors. Proc. Natl. Acad. Sci. USA, 96, (10) p. 5686-90.	

Examiner Signature	<i>David L. Litten</i>	Date Considered	12/21/01
-----------------------	------------------------	--------------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

1c825 U.S. PTO
09/725030

